TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05906043

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Intervention
Description: Exercise intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: ACT will be used for patients with psychological disability as well as for those with sleep disturbance

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: ACT will be used for patients with psychological disability as well as for those with sleep disturbance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic
Description: Use of a probiotic
Study: NCT05617274

Intervention type: PROCEDURE
Intervention: Sectioning of the full arch mandibular fixed prosthesis
Description: The one unit full arch fixed prosthesis is sectioned at the midline into two pieces
Study: NCT05009810

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: astaxanthin 4 mg
Description: They will take astaxanthin 4 mg 1 capsule once daily for 2 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: astaxanthin 6 mg
Description: They will take astaxanthin 6 mg 1 capsule once daily for 2 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will take placebo 1 capsule once daily for 2 months.
Study: NCT01274403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan, Prednisone and Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan, Prednisone and Thalidomide
Study: NCT04010266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RelieVRx headset
Description: RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multi-modality pain management
Description: combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: multi-modality pain management
Description: combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids
Study: NCT04752501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychologically Informed Education
Description: This arm will provide an education intervention which will attempt to address maladaptive psychological behaviors in adolescents with knee pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical Education (Control)
Description: This arm will provide education of basic knee anatomy, lower extremity mechanics, and simple exercises and will not address maladaptive psychological behaviors
Study: NCT04865237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Virus
Description: SARS-CoV-2, intranasally, (1x10\^1 TCID50, 1x10\^2 TCID50 and 1x10\^3 TCID50 or higher, as necessary)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: VEKLURY™
Study: NCT05539807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating Conscious Living
Description: MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group.
Study: NCT05311189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10, Trastuzumab and Chemotherapy
Description: HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
Study: NCT05589077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on Female Athlete Nutritional Concerns
Description: Visual and audio information presented within the Qualtrics system will cover topics on the Female Athlete Triad, Relative Energy Deficiency in Sport, and eating disorders.
Study: NCT05058313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Six weekly photobiomodulation sessions (PBMT) using the MILTA ™ GYNECO vaginal probe.
Study: NCT04452825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer and Aging: Reflections for Elders (CARE) Intervention
Description: For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Work and Supportive Counseling (SWSC) Intervention
Description: The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. For full participants (not training case participants) five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months). Training case participants will follow a slightly condensed schedule.
Study: NCT05215444

Intervention type: DIAGNOSTIC_TEST
Intervention: some prognostic factors
Description: cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count

Intervention type: DIAGNOSTIC_TEST
Intervention: some prognostic factors
Description: cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count
Study: NCT05842148

Intervention type: OTHER
Intervention: Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.
Description: Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).

Intervention type: OTHER
Intervention: Study and recording of post-surgical clinical and pathological data of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.
Description: Control and review of pathological parameters (oncological radicality resection volume, locoregional extension / TNM / multifocality and tumor biological profile).

Intervention type: OTHER
Intervention: Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.
Description: Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).
Study: NCT04657718

Intervention type: DEVICE
Group type: OTHER
Intervention: KODEX-EPD system
Description: Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
Study: NCT05842148

Intervention type: OTHER
Intervention: Study and recording of any associated post-surgical complications (of patients diagnosed with breast cancer undergoing unilateral or bilateral conservative oncoplastic surgery.
Description: Control and review of post-surgical complications (dehiscence, liponecrosis, infection, seroma, hematoma, fibrosis, scar hypertrophy).

Intervention type: OTHER
Intervention: Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.
Description: Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.

Intervention type: OTHER
Intervention: Study and recording of aesthetic and functional post-surgical results related to the quality of life, as data perceived by the surgeon (technical analysis), and by the patient.
Description: Control and review of technical analysis by the surgeon, and of psychosocial well-being, physical discomfort, adverse effects of radiotherapy by the patient collected through the administration of a questionnaire.
Study: NCT05564312

Intervention type: DEVICE
Intervention: Transabdominal ultrasonographic guidance at embryo transfer.
Description: During embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography.

Intervention type: DEVICE
Intervention: Transabdominal ultrasonographic guidance at embryo transfer.
Description: During embryo transfer in each patient, endometrial thickness, uterine cavity dimensions, distance of transfer catheter to the fundus, distance of released air bubble to the fundus, and distance of air bubble to side walls will be systematically measured and recorded under the guidance of transabdominal ultrasonography.
Study: NCT06106958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Participants will receive a home exercise program that consists of 2 exercises and 3 stretches. The exercises include:~* Massage on the bottom of the foot with a ball~* Calf-raises~* Lunge calf-stretch with the knee straight~* Calf-stretch with the knee bent~* Stretch for the bottom of the foot~These exercises are intended to be performed daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Participants will receive a home exercise program that consists of 2 exercises and 3 stretches. The exercises include:~* Massage on the bottom of the foot with a ball~* Calf-raises~* Lunge calf-stretch with the knee straight~* Calf-stretch with the knee bent~* Stretch for the bottom of the foot~These exercises are intended to be performed daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimalist Shoes
Description: Participants will receive a pair of minimalist shoes. They will wear them for an allotted amount of time per day each week, in order to allow for a slow adjustment into the shoes. The protocol is as follows:~* Week 1: 1 hour per day~* Week 2: 2 hours per day~* Week 3: 4 hours per day~* Week 4: 6 hours per day~* Week 5: 8 hours per day~* Week 6: 8 hours per day~* Week 7: 8 hours per day~* Week 8: 8 hours per day
Study: NCT06524856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Master (Pulmonary Exerciser)
Description: During the one-month using the Lung Master at their house, the participant will be using it at least one time every day, either in the morning or in the evening before going to sleep. During the session, the participants will sit upright and try to prolong the inhalation and exhalation breaths through the Lung Master device for at least three seconds. For each session, the participants will try to concentrate on 35-50 breaths in and breaths out which is about 2-5 minutes. Every session can involve using the Pulmonary Exerciser for a minimum of 5 minutes and a maximum of 20 minutes. After each session, participants will be asked to note how long they have used the device and when they have used it. Information from each session will be recorded on the Participant Device Log that will be provided.
Study: NCT06205251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERbreathe Plus IMT
Description: Inspiratory muscle training will be performed using the POWERbreathe Plus IMT (POWERbreathe International Ltd., Warwickshire, UK), a commercially available inspiratory pressure threshold device. In this type of training, airflow is occluded until the generated inspiratory pressure reaches the predetermined threshold, which can be set at increments of 8 cm H2O.~During the first week of training, the target intensity will be set at 50% of baseline maximal inspiratory pressure (MIP.) During the second week, the target intensity will be set at 60% of baseline MIP. Beginning at the third week and for the remainder of the training program, the target intensity will be set at 75% of the participant's baseline MIP. The target volume will be 5 sets of 6 breaths per day (total of 30 breaths per day), separated by 1-minute rest breaks between sets. The frequency of training will be 5 days per week, for a duration of 6 weeks.
Study: NCT05303428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation with low-intensity focused ultrasound
Description: application of LIFU to induce temporary neuromodulation, effects tested with resting state and task based fMRI scanning.
Study: NCT05950698

Intervention type: DEVICE
Intervention: Holter Faros 360° EKG (Bittium Corporation)
Description: Patients will lie down on the examination table, a five-lead ECG will be attached to their chest, and they should rest for 5 minutes before starting the ECG recording. ECG data will be collected for a 15-minute period Heart Rate Variability (HRV) recording will be performed between 09:00 and 12:00 in a fixed examination room to minimize environmental factors and diurnal fluctuations in autonomic nervous system functioning.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck Depression Inventory (BDI)
Description: The BDI assesses the depression severity. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scales - HADS
Description: The HADS assesses the anxiety and depression symptoms. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
Study: NCT05623319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Olaparib
Description: Patients will receive pembrolizumab 200 mg 1q21 and chemotherapy -platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute) 1q21 plus etoposide 100 mg/m2 1-3q21- for 4 cycles (Induction Phase). In case of responsive or stable disease, patients will receive pembrolizumab 200 mg 1q21 plus olaparib 300 mg twice daily until progression (Maintenance Phase) or up to a maximum of 35 cycles.
Study: NCT05950698

Intervention type: DIAGNOSTIC_TEST
Intervention: Three Factor Eating Questionnaire-R21 - TFEQ-R21
Description: The TFEQ-R21assesses the quality of eating behavior. It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).

Intervention type: DIAGNOSTIC_TEST
Intervention: hort-Form Health Survey-36 itens - SF-36
Description: he TFEQ-R21assesses the quality of life Divided into different areas (functional capacity, general health status, pain, vitality, social aspects, emotional aspects, and mental health). It will be administered before bariatric surgery at time T0 and 3-6-12-24 months after bariatric surgery (T1-T2-T3-T4).
Study: NCT06245252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive stretching for group A
Description: A description of stretch is performed 3 times per week for 12 weeks. The stretches included (in the order they were applied): Seated knee flexor (bilateral); Seated knee flexor-hip adductor (bilateral); Seated shoulder lateral flexor (bilateral); Supine hip flexor- knee extensor (unilateral). Seated hip external rotators, extensor (unilateral); Seated shoulder extensors, adductors, retractors (unilateral). Supine knee flexor-plantar flexor (unilateral); Prone hip flexor (unilateral); Seated shoulder flexors, depressors (bilateral); Seated shoulder and elbow flexors (unilateral).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation for group b
Description: reated by 30 minutes electrical stimulation three times per week for 12 weeks
Study: NCT05499533

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant site preparation
Description: a hole were created in the edentulous ridge area before implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant site preparation
Description: a hole were created in the edentulous ridge area before implant placement
Study: NCT05893160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAN101 SR
Description: The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo formulation
Study: NCT06574516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Description: Ibuprofen every 8 hours for three days post operatively
Study: NCT04640948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal therapy
Description: Controlled oxygen administration using at least 20 L/min of flow rate and titrated up as tolerated. Titration of supplemental oxygen to an arterial saturation between 88 - 92%.
Study: NCT06574516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Description: Ibuprofen every 8 hours for three days post operatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Paracetamol PRN for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol PRN for three days
Study: NCT05795985

Intervention type: DIAGNOSTIC_TEST
Intervention: calprotectin levels
Description: dosage of calprotectin levels in patients with abdominal pain
Study: NCT06725160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Coaching
Description: Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: General parent support based on child directed interactions skills from standard PCIT.
Study: NCT06348667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific ankle stability exercises
Description: Exercise program specifically designed to address ankle dorsiflexion and mediolateral displacement of the center of pressure, using the described device (BB). Done twice a week for 5 weeks.
Study: NCT06497816

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06348667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy exercises program
Description: Conventional exercise program performed in the center twice a week, of which all participants are part.
Study: NCT05621993

Intervention type: DRUG
Intervention: Azvudine
Description: Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.

Intervention type: DRUG
Intervention: Azvudine
Description: Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
Study: NCT05421559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: removal of the diseased thyroid gland by conventional method vs transection method of sternothryroid muscle
Study: NCT05621993

Intervention type: DRUG
Intervention: Azvudine
Description: Azvudine is a small molecular antiviral drug. On August 9, 2022, Azvudine was included in the Diagnostic and therapeutic protocol for COVID-9 in China.
Study: NCT05879497

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104 PET/CT
Description: Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration.
Study: NCT05613829

Intervention type: OTHER
Intervention: Burn surgery
Description: Patients underwent burn surgery
Study: NCT05913024

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enterovirus Type 71 Vaccine
Description: Participants received two doses of the vaccine, 28 days apart
Study: NCT04640948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen
Description: Controlled oxygen administration using (venturi mask or nasal cannulae) titrated to an arterial saturation between 88 - 92% as the initial oxygen administration method with a flow rate of \<20 L/min.
Study: NCT05913024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enterovirus Type 71 Vaccine
Description: Participants received two doses of the vaccine, 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enterovirus Type 71 Vaccine
Description: Participants received two doses of the vaccine, 28 days apart
Study: NCT05492864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extrusion of the anterior teeth
Description: sectional leveling and alignment of the teeth, then using of the extrusion arch as an overlay wire to treat the open bite
Study: NCT06501508

Intervention type: DEVICE
Intervention: Stratafix Symmetric
Description: Use of Stratafix Symmetric for primary fascial closure
Study: NCT05233956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LNG IUS
Description: Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COCs
Description: FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
Study: NCT05732740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empower@Home:Connected
Description: Cognitive behavioral therapy
Study: NCT06291831

Intervention type: DRUG
Intervention: nirmatrelvir, ritonavir
Description: Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
Study: NCT05082545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2002 and SHR-1316
Description: Cohort study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2002 and SHR-1316
Description: Cohort study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2002 and SHR-1316
Description: Cohort study